Dianne L Judd

US Patent:

20080075628, Mar 27, 2008

Filed:

Sep 27, 2006

Appl. No.:

11/535762

Inventors:

Dianne Judd - Minneapolis MN, US
William Ferris - Minneapolis MN, US

Assignee:

MEDTRONIC, INC. - Minneapolis MN

International Classification:

A61L 2/00

US Classification:

422 22, 424423

Abstract:

A sterilized medical device comprising minocycline and rifampin is described. The device is setrerilized by e-beam raditation such that degradation of minocycline and rifampin is minimized. Methods for sterilizing minocycline and rifampin-containing devices by e-beam radiation and methods of manufacturing devices, which methods include e-beam sterilization, are also described.

US Patent:

20090204104, Aug 13, 2009

Filed:

May 4, 2005

Appl. No.:

11/568779

Inventors:

Patrice Tremble - Santa Rosa CA, US
Dianne Judd - Minneapolis MN, US
Kishore Udipi - Santa Rosa CA, US
Peiwen Cheng - Santa Rosa CA, US
Rangarajan Sundar - Santa Rosa CA, US
Kaushik A. Patel - Windsor CA, US
Eugene Tedeschi - Santa Rosa CA, US

Assignee:

Medtronic Vascular, Inc - Santa Rosa CA

International Classification:

A61M 25/10
A61M 25/06
A61K 9/14
A61P 9/02

US Classification:

604509, 604508, 424489

Abstract:

The invention provides a method of delivering a therapeutic agent to the adventitia of a vessel using a catheter-based microsyringe. A therapeutic agent is formed into microparticles, which are dispersed throughout an appropriate liquid carrier to form a therapeutic mixture. A catheter is provided that includes a microsyringe operably attached to an actuator. The microsyringe includes a hollow needle in fluid communication with a therapeutic agent delivery conduit. The catheter is introduced into a target area of a vessel. The actuator is operated to thrust the needle into a wall of the vessel. The therapeutic mixture is supplied to the therapeutic agent delivery conduit and delivered through the conduit to the needle and thereby into the adventitia of the vessel. The actuator is again operated to withdraw the needle from the wall of the vessel and to enclose it within the actuator. The catheter is then removed from the vessel.

US Patent:

20130244937, Sep 19, 2013

Filed:

Sep 2, 2012

Appl. No.:

13/602187

Inventors:

William Van Antwerp - Valencia CA, US
Andrew J. L. Walsh - Minneapolis MN, US
Lian Luo - Plymouth MN, US
Dianne L. Judd - Minneapolis MN, US

Assignee:

NILE THERAPEUTICS, INC. - San Mateo CA
MEDTRONIC, INC. - Minneapolis MN

International Classification:

A61K 38/22

US Classification:

514 124

Abstract:

Therapeutic compositions containing chimeric natriuretic peptides for treating chronic kidney disease alone, heart failure alone, or chronic kidney disease with concomitant heart failure are described. The therapeutic compositions have enhanced stability characteristics to facilitate storage and delivery by provisioning apparatuses under conditions of elevated temperature and mechanical stress. Methods for increasing the stability of therapeutic compositions containing chimeric natriuretic peptides are further described.

US Patent:

20070231361, Oct 4, 2007

Filed:

Mar 28, 2006

Appl. No.:

11/277637

Inventors:

David Brin - West Newbury MA, US
Jack Chu - Santa Rosa CA, US
Prema Ganesan - San Francisco CA, US
Dianne Judd - Minneapolis MN, US
Michel Letort - Prevessins, FR
Patrice Tremble - Santa Rosa CA, US
Eugene Tedeschi - Santa Rosa CA, US

Assignee:

Medtronic Vascular, Inc. - Santa Rosa CA

International Classification:

A61K 31/202

US Classification:

424423000, 514560000

Abstract:

Methods of treating an aneurysm in a patient in need thereof are provided. The methods comprise delivering to a treatment site an effective amount of a fatty acid inhibitor of a matrix metalloproteinase (MMP) such that the fatty acid inhibitor of the MMP causes the regression of a pre-existing aneurysm. Additionally, an implantable medical device is provided for implanting in a vessel wall of a patient comprising a structural support and a fatty acid inhibitor of an MMP.

US Patent:

20160051632, Feb 25, 2016

Filed:

Nov 6, 2015

Appl. No.:

14/934617

Inventors:

- Beverly Hills CA, US
Andrew J. L. Walsh - Minneapolis MN, US
Lian Luo - Plymouth MN, US
Dianne L. Judd - Minneapolis MN, US

Assignee:

CAPRICOR THERAPEUTICS, INC. - Beverly Hills CA

International Classification:

A61K 38/22
A61K 9/08
A61K 47/02
A61K 47/10
A61K 47/18

Abstract:

Therapeutic compositions containing chimeric natriuretic peptides for treating chronic kidney disease alone, heart failure alone, or chronic kidney disease with concomitant heart failure are described. The therapeutic compositions have enhanced stability characteristics to facilitate storage and delivery by provisioning apparatuses under conditions of elevated temperature and mechanical stress. Methods for increasing the stability of therapeutic compositions containing chimeric natriuretic peptides are further described.

US Patent:

20160032268, Feb 4, 2016

Filed:

Mar 4, 2015

Appl. No.:

14/638321

Inventors:

- Minneapolis MN, US
Dianne L. Judd - Minneapolis MN, US
Cindy Roberson - Plymouth MN, US
Eric Hall - Plymouth MN, US

Assignee:

Medtronic, Inc. - Minneapolis MN

International Classification:

C12N 9/80

Abstract:

A method for the extraction and purification of urease from jack beans or other natural sources of urease. The method provides an efficient way to obtain purified urease from natural sources. The method can include defatting the natural sources of urease, extracting the urease from impurities, and further purification of the extracted urease.

US Patent:

20150038418, Feb 5, 2015

Filed:

Jul 19, 2012

Appl. No.:

14/235364

Inventors:

William Van Antwerp - Valencia CA, US
Dianne Judd - Minneapolis MN, US
Andrew Walsh - Minneapolis MN, US
Lian Luo - Plymouth MN, US

Assignee:

MEDTRONIC, INC. - Minneapolis MN

International Classification:

C07K 14/58

US Classification:

514 124

Abstract:

Therapeutic compositions containing natriuretic peptides for treating chronic kidney disease alone, heart failure alone, or chronic kidney disease with concomitant heart failure are described. The therapeutic compositions have enhanced stability characteristics to facilitate storage and delivery by provisioning apparatuses under conditions of elevated temperature and mechanical stress. Methods for increasing the stability of therapeutic compositions containing natriuretic peptides are further described.